Skip to main content

Market Overview

Mirati Therapeutics Sitravatinib Data, Explained

Mirati Therapeutics Sitravatinib Data, Explained

Mirati Therapeutics, Inc. (NASDAQ: MRTX) shares are skyrocketing Friday in reaction to its announcement of positive preliminary data from two ongoing clinical trials of its non-small cell lung cancer, or NSCLC, candidate sitravatinib.

The company said the data will be presented at the IASLC 2017 Chicago Multidisciplinary Symposium in Thoracic Oncology on Friday.

At time of writing, shares of Mirati were up 120 percent to $10.40.

See Also: Attention Biotech Investors: September Ushers In Another Slew Of PDUFA Catalysts

Leerink analysts Michael Schmidt, Varun Kumar and Jonathan Chang indicated that a new anecdotal case report of a single agent response, as well as clinical activity in combination with Bristol-Myers Squibb Co (NYSE: BMY)‘s Opdivo in difficult to treat NSCLC patients not responding anymore to anti-PDI inhibitors will also be presented.

Leerink sees these early updates as positive news for Mirati. Additionally, the firm said this could potentially have a beneficial effect on the accrual of ongoing single agent cohorts, as well as development prospects in combination with Opdivo.

"Mirati's pipeline agents hold the promise to address compelling niche markets in cancer patients with rare genetic alterations," the analysts said in a note.

However, Leerink noted that trial enrollment has been slow and differentiation from other agents approved or in development is difficult to determine.

The firm views the first Opdivo combo results as an important positive data point, while it looks forward to additional results in a larger patient cohort.

As such, Leerink raised its price target by $2 to $9 to include probability-adjusted value for the Opdivo combination opportunity for sitravatinib in non-squamous NSCLC. The firm has a Market Perform rating on shares.

Latest Ratings for MRTX

Mar 2021OppenheimerMaintainsOutperform
Mar 2021HC Wainwright & Co.MaintainsBuy
Jan 2021HC Wainwright & Co.MaintainsBuy

View More Analyst Ratings for MRTX
View the Latest Analyst Ratings


Related Articles (MRTX)

View Comments and Join the Discussion!

Posted-In: Jonathan Chang LeerinkAnalyst Color Health Care Price Target Top Stories Analyst Ratings General Best of Benzinga

Latest Ratings

CSXRaymond JamesMaintains105.0
UPSRaymond JamesMaintains200.0
XPORaymond JamesMaintains145.0
JBHTRaymond JamesMaintains180.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at